Seqens Seqens

X
[{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Harrow Launches VIGAMOX in the U.S.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Moxifloxacin Hydrochloride

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

            Lead Product(s): Moxifloxacin Hydrochloride

            Therapeutic Area: Infections and Infectious Diseases Product Name: Vigamox

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 31, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY